Check our poster at #GU23. Adverse cardiovascular and thromboembolic events during intense NeoAdj Androgen Blockade before Prostatectomy. Raise concerns for this future strategy. ⁦HSL MedOnc Fellows⁩ ⁦Diogo Assed Bastos⁩

Countdown to #ASCO23 ‼️

Happy to share that I’m starting a new position as an Editorial Fellow at JIPO Editors! Grateful for the opportunity to work w/ the terrific editorial board while peer reviewing, proofreading, and disseminating content on #immunotherapy and #precisiononcology via social media!

Thank you Hospital Sirio Libanes Brenda Gumz on a superb Memorial Sloan Kettering Cancer Center MSK Department of Medicine #GIFellows Monthly Conference. Great learning and engagement on #insulinoma.

🌎🖥️ always connected Sírio-Libanês HSL MedOnc Fellows

📢 Great retrospective from Mayo Clinic ! 📍dMMR/MSI PDAC are rare (1-2% of PDAC) ♦️KN158 outcomes for M+ are poorer than RWD but grant ICI agnostic approval 🆚 could we de-escalate bi/tri modality treatment? ❇️ Guidelines should be revised! #immunotherapy #PancreaticCancer

⏰ Countdown to #ESMO23 ESMO - Eur. Oncology! Meet us on Saturday and check out our work on survival predictors among TMB-low #cancer patients treated with #immunotherapy galante_lab Pedro A.F. Galante 🧬🚴🇧🇷 Diego Holanda Beatriz Awni Denis Jardim

Just had a great time presenting my work on OS predictors among TMB-low #cancer patients treated with #Immunotherapy at #ESMO23 & with the plus of receiving the visit from the IO master and JIPO Editors mentor Aung Naing ! Thank you for the support 🇧🇷 Denis Jardim galante_lab

A rare case of primary carcinosarcoma of the peritoneum after risk-reducing BSO in a BRCA2 pathogenic variant carrier & BC survivor. 🧬 Thank you ⁦⁦Daniele Assad Suzuki⁩ & team ⁦Sírio-Libanês⁩ #casereport #oncology #breastcancer #BRCA karger.com/cro/article/17…

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline ascopubs.org/doi/10.1200/JC… All women with breast cancer < 65 should get genetic testing. devem fazer o teste genético! Hospital Sírio-Libanês: única instituição da América Latina convidada.

Germline testing🧬 should be revisited for many cancer types to improve #cancercare. This ⁦⁦ASCO⁩ update frames a beautiful work on the recommendations for #BreastCancer patients w/ the contribution of the 🇧🇷oncogenetic leader Maria Isabel Achatz ascopubs.org/doi/10.1200/JC…

Comments on my personal top 4 #GI24 abstracts (1/4): 1. NETTER-2 177Lu-DOTATATE vs high dose octreotide as 1L treatment of G2 or G3 GEP-NET (Ki67 between 10% and 55%): ⬆️ PFS (22.5 vs 8.5 mo, HR 0.27) ⬆️ ORR (43% vs 9%) I did not expect such good numbers. OncoAlert 1/

Thrilled to receive Radiation Oncology’s academic excellence in research award for 2nd consecutive yr! Grateful to my @sunnybrook mentors & coauthors arjun sahgal Dr Soliman, Liam Lawrance, Angus Lau Jay Detsky MD. Tremendous & innovative research on ADC changes for recurrence prediction #GBM

Our ability to enhance #immunotherapy efficacy can be closely related to our capacity to overcome TME immunosuppression. Metabolism-directed targeted 🎯 therapies are (among others) great examples of #investigational #phaseI strategies to revert cold TME Aung Naing MD Anderson Cancer Center

Amazing time w/ the MD Anderson Cancer Center GI team! CCA pts may present to clinic with multiple co-occurrent genomic alterations 🎯🎯🎯 and target Tx sequencing strategies can improve survival outcomes compared with sequencing non-matched therapies. Happy to collaborate!

Amazing work! This platform will help oncologists and patients across the country as it changes the landscape of clinical trial information and access in Brazil. This needs to be highlighted! SBOC ASCO JCO Global Oncology Jill Feldman Julia Maués

R0 resection is associated w/ OS outcomes for #PDAC. However, rare complications associated w/ mesopancreas excision as recurrent neurogenic shock can preclude patients from receiving proper adjuvant Tx. Check out our multidisciplinary report gs.amegroups.org/article/view/1… HSL MedOnc Fellows

One of our star Phase 1 fellows! Camila Braganca Xavier Who will become a MDACC GI Onc doc! MD Anderson Cancer Center

💊 Can DFS be used as a surrogate for OS in early-stage pancreatic cancer trials? 📈 In a meta-analysis of 29 RCTs (n=6777), DFS strongly correlated with OS (R=0.70 adjuvant | R=0.90 neoadjuvant). 📍 DFS may be a reliable surrogate endpoint for OS. bmjoncology.bmj.com/content/bmjonc…

After many years participating on both sides —as mentor and mentee— I can say that this is one of the most exciting moments of the meeting! Sign up for #ASCO25 encounters if you have the chance! ⁦ASCO TECAG⁩ ➡️ Topical Mentoring Opportunities - ASCO asco.org/career-develop…